934 related articles for article (PubMed ID: 19539108)
21. Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support.
Brugger W; Bacon P; Lawrinson S; Romieu G
Crit Rev Oncol Hematol; 2009 Dec; 72(3):265-9. PubMed ID: 19596586
[TBL] [Abstract][Full Text] [Related]
22. Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients.
Chan A; Leng XZ; Chiang JY; Tao M; Quek R; Tay K; Lim ST
Asia Pac J Clin Oncol; 2011 Mar; 7(1):75-81. PubMed ID: 21332654
[TBL] [Abstract][Full Text] [Related]
23. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy.
Yang BB; Kido A; Shibata A
Pharmacotherapy; 2007 Oct; 27(10):1387-93. PubMed ID: 17896894
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
[TBL] [Abstract][Full Text] [Related]
25. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.
Aapro M; Schwenkglenks M; Lyman GH; Lopez Pousa A; Lawrinson S; Skacel T; Bacon P; von Minckwitz G
Crit Rev Oncol Hematol; 2010 Jun; 74(3):203-10. PubMed ID: 19748281
[TBL] [Abstract][Full Text] [Related]
26. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
27. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.
Romieu G; Clemens M; Mahlberg R; Fargeot P; Constenla M; Schütte M; Easton V; Skacel T; Bacon P; Brugger W
Crit Rev Oncol Hematol; 2007 Oct; 64(1):64-72. PubMed ID: 17317205
[TBL] [Abstract][Full Text] [Related]
28. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
29. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.
Rivera E; Erder MH; Moore TD; Shiftan TL; Knight CA; Fridman M; Brannan C; Danel-Moore L; Hortobagyi GN;
Cancer; 2003 Jul; 98(2):222-8. PubMed ID: 12872339
[TBL] [Abstract][Full Text] [Related]
30. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
Waladkhani AR
Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
[TBL] [Abstract][Full Text] [Related]
31. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
Rader M
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
[TBL] [Abstract][Full Text] [Related]
32. Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.
Lokich JJ
Am J Clin Oncol; 2006 Aug; 29(4):361-3. PubMed ID: 16891862
[TBL] [Abstract][Full Text] [Related]
33. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2017 Dec; 33(12):2107-2113. PubMed ID: 28958157
[TBL] [Abstract][Full Text] [Related]
34. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
Yamamoto N; Sekine I; Nakagawa K; Takada M; Fukuoka M; Tanigawara Y; Saijo N
Jpn J Clin Oncol; 2009 Jul; 39(7):425-30. PubMed ID: 19395467
[TBL] [Abstract][Full Text] [Related]
35. Rational selection of patients for antibacterial prophylaxis after chemotherapy.
Cullen MH; Billingham LJ; Gaunt CH; Steven NM
J Clin Oncol; 2007 Oct; 25(30):4821-8. PubMed ID: 17947731
[TBL] [Abstract][Full Text] [Related]
36. Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients.
Mathew S; Adel N; Rice RD; Panageas K; Duck ET; Comenzo RL; Kewalramani T; Nimer SD
Bone Marrow Transplant; 2010 Oct; 45(10):1522-7. PubMed ID: 20062102
[TBL] [Abstract][Full Text] [Related]
37. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
38. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
Cullen M; Steven N; Billingham L; Gaunt C; Hastings M; Simmonds P; Stuart N; Rea D; Bower M; Fernando I; Huddart R; Gollins S; Stanley A;
N Engl J Med; 2005 Sep; 353(10):988-98. PubMed ID: 16148284
[TBL] [Abstract][Full Text] [Related]
39. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
40. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]